Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1
| Autor: | Nir Osherov, Ronen Ben-Ami, Alma Morogovsky, Mariana Handelman, Wei Liu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Antifungal Agents
Triazole Azole resistance Reductase medicine.disease_cause Aspergillus fumigatus Microbiology Fungal Proteins chemistry.chemical_compound Mechanisms of Resistance Drug Resistance Fungal Humans Medicine Pharmacology (medical) HMGB1 Protein Gene Pharmacology Mutation biology business.industry Triazoles biology.organism_classification Pulmonary aspergillosis Infectious Diseases chemistry CCPA Pulmonary Aspergillosis business |
| Zdroj: | Antimicrob Agents Chemother |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.01089-21 |
| Popis: | Triazole resistance in the pathogenic mold Aspergillus fumigatus has increased worldwide, posing a growing therapeutic challenge. Recently, mutations in the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase gene ( hmg1 ) have been associated with triazole resistance. Here, we describe a novel E306K triazole resistance-conferring mutation in the HMG-CoA reductase gene from an Israeli patient with chronic cavitary pulmonary aspergillosis (CCPA). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|